Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 1
2011 2
2012 1
2013 1
2014 2
2015 3
2016 4
2018 2
2019 4
2020 5
2021 2
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition.
Priem B, van Leent MMT, Teunissen AJP, Sofias AM, Mourits VP, Willemsen L, Klein ED, Oosterwijk RS, Meerwaldt AE, Munitz J, Prévot G, Vera Verschuur A, Nauta SA, van Leeuwen EM, Fisher EL, de Jong KAM, Zhao Y, Toner YC, Soultanidis G, Calcagno C, Bomans PHH, Friedrich H, Sommerdijk N, Reiner T, Duivenvoorden R, Zupančič E, Di Martino JS, Kluza E, Rashidian M, Ploegh HL, Dijkhuizen RM, Hak S, Pérez-Medina C, Bravo-Cordero JJ, de Winther MPJ, Joosten LAB, van Elsas A, Fayad ZA, Rialdi A, Torre D, Guccione E, Ochando J, Netea MG, Griffioen AW, Mulder WJM. Priem B, et al. Among authors: van elsas a. Cell. 2020 Oct 29;183(3):786-801.e19. doi: 10.1016/j.cell.2020.09.059. Cell. 2020. PMID: 33125893 Free PMC article.
Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure.
Di Trani CA, Cirella A, Arrizabalaga L, Alvarez M, Bella Á, Fernandez-Sendin M, Russo-Cabrera JS, Gomar C, Ardaiz N, Teijeira A, Bolaños E, González-Gomariz J, Otano I, Aranda F, Palencia B, Segués A, Huang S, van Duijnhoven SMJ, van Elsas A, Melero I, Berraondo P. Di Trani CA, et al. Among authors: van elsas a. Mol Ther Nucleic Acids. 2023 Jul 19;33:599-616. doi: 10.1016/j.omtn.2023.07.020. eCollection 2023 Sep 12. Mol Ther Nucleic Acids. 2023. PMID: 37637207 Free PMC article.
Alkaline phosphatase as a treatment of sepsis-associated acute kidney injury.
Peters E, van Elsas A, Heemskerk S, Jonk L, van der Hoeven J, Arend J, Masereeuw R, Pickkers P. Peters E, et al. Among authors: van elsas a. J Pharmacol Exp Ther. 2013 Jan;344(1):2-7. doi: 10.1124/jpet.112.198226. Epub 2012 Nov 6. J Pharmacol Exp Ther. 2013. PMID: 23131595 Review.
Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies.
Dang X, Guelen L, Lutje Hulsik D, Ermakov G, Hsieh EJ, Kreijtz J, Stammen-Vogelzangs J, Lodewijks I, Bertens A, Bramer A, Guadagnoli M, Nazabal A, van Elsas A, Fischmann T, Juan V, Beebe A, Beaumont M, van Eenennaam H. Dang X, et al. Among authors: van elsas a. MAbs. 2023 Jan-Dec;15(1):2285285. doi: 10.1080/19420862.2023.2285285. Epub 2023 Nov 27. MAbs. 2023. PMID: 38010385 Free PMC article.
Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
Guelen L, Fischmann TO, Wong J, Mauze S, Guadagnoli M, Bąbała N, Wagenaars J, Juan V, Rosen D, Prosise W, Habraken M, Lodewijks I, Gu D, Stammen-Vogelzangs J, Yu Y, Baker J, Lutje Hulsik D, Driessen-Engels L, Malashock D, Kreijtz J, Bertens A, de Vries E, Bovens A, Bramer A, Zhang Y, Wnek R, Troth S, Chartash E, Dobrenkov K, Sadekova S, van Elsas A, Cheung JK, Fayadat-Dilman L, Borst J, Beebe AM, Van Eenennaam H. Guelen L, et al. Among authors: van elsas a. J Immunother Cancer. 2022 Sep;10(9):e005049. doi: 10.1136/jitc-2022-005049. J Immunother Cancer. 2022. PMID: 36100308 Free PMC article.
31 results